Loading organizations...
Loading organizations...
Develops novel small-molecule therapies for cancer and hepatitis B.
Ascentage Pharma has raised $237.6M across 3 funding rounds.
Ascentage Pharma has raised $237.6M in total across 3 funding rounds.
Ascentage Pharma has raised $237.6M in total across 3 funding rounds.
Ascentage Pharma's investors include Teng Yue Partners, Lawrence Tian, ArrowMark Partners, CCB International, CTS Capital, HDY International Investment, Future Industry Ventures, Efung Capital, Hidragon Capital, KIP Capital, Oriza Ventures, Shiyu Capital.
Ascentage Pharma has raised $237.6M across 3 funding rounds. Most recently, it raised $150.0M Series C in July 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 18, 2018 | $150.0M Series C | Teng Yue Partners, Lawrence Tian | ArrowMark Partners, CCB International, CTS Capital, HDY International Investment |
| Jan 9, 2017 | $72.1M Series B | Future Industry Ventures | Efung Capital, Hidragon Capital, KIP Capital, Oriza Ventures, Shiyu Capital, YuanMing Capital |
| Aug 15, 2015 | $15.5M Series A | Oriza Ventures, YuanMing Capital | BioVentures Investors, Efung Capital, Grains Valley Venture Capital |